,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'congrat', 'breast']
#asco2022 destiny-04. ild as expected. my thoughts: best in show for breast cancer this year. her2-low now on the table for adcs as a class. there is an accompanying nejm paper. the audience goes wild in a way i have not seen since the her2 2005 rock concert. congrats to dr modi.
Professor of Medicine, Stanford University; breast cancer doc